BIOFILCHEM · NSE
Biofil Chemicals & Pharmaceuticals Limited
₹32.33
+0.12% (+₹0.04)
Prev. close
₹32.29
Volume
9,891
Delivery %
78.4%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Biofil Chemicals & Pharmaceuticals Limited
Biofil Chemicals and Pharmaceuticals Limited engages in the manufacturing and trading of pharmaceutical products in India. It operates through Pharma and Chemical segments. The company offers basic drugs and chemicals, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrus fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. It also provides ferrous sulphate in crystal, exsiccated, and granular form; microcrystalline cellulose powder; cellulose powder; calcium carbonate; and sodium chloride. In addition, the company offers job work facility for manufacturing of pharmaceuticals drug. Biofil Chemicals and Pharmaceuticals Limited was founded in 1985 and is based in Indore, India
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ketan Shah
Headquarters
Indore
Employees
24
Website
biofilgroup.netExchange
View on NSE ↗Key stats
Market cap
₹52.61 Cr
P/E ratio (TTM)
107.8
EPS (TTM)
₹0.30
Beta (1Y · daily vs NIFTY 50)
0.76
Beta (5Y · monthly vs NIFTY 50)
1.45
Shares float
70.97 L
EPS · quarter ended Jun 2026
₹0.07
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Other assets floored at zero for years where fixed and current assets exceeded reported total assets.
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹35.75 Cr | ₹22.38 Cr | ₹30.04 Cr | ₹40.04 Cr | ₹33.40 Cr | ₹28.40 Cr | |
| EBITDA | ₹2.40 Cr | ₹1.48 Cr | ₹1.26 Cr | ₹1.31 Cr | ₹1.15 Cr | ₹3.73 Cr |
| ₹1.25 Cr | ₹69.84 L | ₹56.04 L | ₹70.93 L | ₹55.78 L | ₹2.79 Cr | |
| Diluted EPS | ₹0.76 | ₹0.44 | ₹0.34 | ₹0.44 | ₹0.34 | ₹1.71 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹33.24 Cr | ₹18.73 Cr | ₹31.40 Cr | ₹47.08 Cr | ₹50.95 Cr | ₹42.84 Cr | |
| ₹42.98 L | ₹46.47 L | ₹52.23 L | ₹43.89 L | ₹47.13 L | ₹3.02 Cr | |
| Stockholders' equity | ₹16.13 Cr | ₹16.83 Cr | ₹17.30 Cr | ₹18.20 Cr | ₹18.78 Cr | ₹21.56 Cr |
Long-term debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1.11 Cr | ₹-22.00 L | ₹-11.00 L | ₹2.39 Cr | ₹-1.92 Cr | ₹-60.00 L | |
| Investing cash flow | ₹-9.61 L | ₹-6.99 L | ₹-1.06 L | ₹-2.29 L | ₹-10.01 L | ₹1.14 Cr |
| ₹-82.64 L | ₹-58,000 | ₹1.51 L | ₹-12.49 L | ₹-45,000 | ₹2.54 Cr | |
| Capital expenditure | ₹-56.67 L | ₹-6.99 L | ₹-1.06 L | ₹-2.29 L | ₹-10.01 L | ₹-20.05 L |
| End cash position | ₹44.05 L | ₹14.49 L | ₹3.76 L | ₹2.28 Cr | ₹25.53 L | ₹3.33 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 21–Jun 25(17Q) | Sep 25–Jun 26(4Q) |
|---|---|---|
| Promoter | 46.82% | 46.79% |
| Public | 53.18% | 53.21% |
| Employee trusts | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Biofil Chemicals & Pharmaceuticals Limited | ₹52.61 Cr | ₹32.33 | 107.8 | 2.44 | 12.9% | 0.14 | -15.0% | -24.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 25
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.